Abstract

N/A

Highlights

  • ▪ Sarecycline, a narrow-spectrum tetracycline-class drug, is FDA-approved for moderate-to-severe acne vulgaris in patients 9 years of age and older

  • ▪ Oral antibiotics are the mainstay treatment for moderate-to-severe acne vulgaris

  • ▪ Sarecycline exhibits potent anti-inflammatory activity and activity against C. acnes but reduced activity against Gram-negative bacteria commonly found in the gut; these characteristics may contribute to its low potential for antibiotic resistance and favorable safety and tolerability profile. 3

Read more

Summary

Introduction

▪ Oral antibiotics are the mainstay treatment for moderate-to-severe acne vulgaris. ▪ Sarecycline, a narrow-spectrum tetracycline-class drug, is FDA-approved for moderate-to-severe acne vulgaris in patients 9 years of age and older.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.